GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,555.00
+5.00 (+0.32%)
As of 4:37PM BST. Market open.
Stock chart is not supported by your current browser
Previous Close 1,550.00
Open 1,544.00
Bid 1,500.00 x 175400
Ask 1,560.00 x 417900
Day's Range 1,536.80 - 1,557.80
52 Week Range 1,408.80 - 1,648.80
Volume 19,978,610
Avg. Volume 8,085,809
Market Cap 76.926B
Beta (3Y Monthly) 0.95
PE Ratio (TTM) 19.81
EPS (TTM) 78.50
Earnings Date Jul 24, 2019
Forward Dividend & Yield 0.92 (5.85%)
Ex-Dividend Date 2019-05-16
1y Target Est 1,644.50
  • The money behind vaccines
    CNBC Videos 8 days ago

    The money behind vaccines

    Vaccines are one of the biggest successes of modern medicine. They save up to 3 million people worldwide every year. From research and discovery to product development, it can cost up to a billion dollars to make one vaccine, and that process — can last up to 15 years. During the past few decades the number of companies producing vaccines has dwindled to just a handful. The four big drug companies that now dominate the market are Merck, Pfizer, Sanofi Pasteur and GlaxoSmithKline.

  • Reuters 3 days ago

    Trade rhetoric weighs on European shares

    European shares dropped on Friday after three days of gains, as Beijing ratcheted up its war of words with Washington over trade, weighing on risk appetite. The pan-European STOXX 600 index was down 0.7% by 0720 GMT, though it was still looking at its best weekly performance since in 1-1/2 months. The Communist Party's People's Daily used a front page commentary to say the trade war would never bring China down, after telecoms equipment giant Huawei Technologies Co Ltd was put on a U.S. blacklist.

  • Reuters 3 days ago

    GSK and Novartis liniment marketing misled Australian consumers - court

    The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday. The court said the companies admitted marketing Voltaren Osteo Gel as a treatment for osteoarthritis-related pain when its ingredients were the same as a cheaper Voltaren product, Emulgel. Judge Robert Bromwich said in a written decision that it was part of a "deliberate and considered marketing strategy".

  • GuruFocus.com 4 days ago

    How to Invest in Biotech: Known Your Catalysts

    The biotechnology and pharmaceutical industry has something for everyone. Whether you are looking for a mature dividend aristocrat like GlaxoSmithKline (GSK) or a small-cap upstart like Sarepta (SRPT) that can double in value overnight, the sector will provide an option that suits your preferred risk-reward profile. Warning! GuruFocus has detected 5 Warning Sign with GSK.

  • PR Newswire 4 days ago

    Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK

    Expands global footprint for complex API manufacturing WALTHAM, Mass. , May 16, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that ...

  • GlobeNewswire 5 days ago

    Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

    Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.

  • Stanford Dad Accused of $6.5 Million Payment in College Scandal Has a New Problem
    Bloomberg 6 days ago

    Stanford Dad Accused of $6.5 Million Payment in College Scandal Has a New Problem

    Shandong Buchang Pharmaceuticals Co., whose chairman Zhao Tao has been caught up in the U.S. college admissions scandal, said in a statement Monday that it had received questions from the stock exchange over why its sales expenses amounted to a higher-than-average 59% of the company’s 2018 revenue of 13.7 billion yuan ($1.99 billion). The company, which sells herbal medicines and bio-pharmaceuticals, said that the sales expenses were for general marketing and consulting, but did not explain why it was higher than the industry average.

  • Fundamentals Of How China Makes Its Money (BABA, PFE)
    Investopedia 7 days ago

    Fundamentals Of How China Makes Its Money (BABA, PFE)

    China has the first or second largest GDP in the world but is not nearly as developed as others in the top 10.

  • Top vaccine makers Merck and Pfizer target China and older adults next
    CNBC 8 days ago

    Top vaccine makers Merck and Pfizer target China and older adults next

    Four giant companies now dominate global vaccine sales. With newer and more expensive vaccines becoming available, the market value of vaccines could rise to $100 billion by 2025.

  • Reuters 11 days ago

    GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

    The two pharmaceutical giants in December said they would combine their consumer health businesses in a joint venture that would be 68 percent-owned by GSK. The Australian Competition and Consumer Commission (ACCC) said products produced and sold by GSK and Pfizer in Australia would face strong competition from other players. For example, GSK's well-known pain management product - Panadol - would face strong competition from Reckitt Benckiser's Nurofen.

  • Reuters 11 days ago

    Australia's anti-trust watchdog gives go-ahead for GSK-Pfizer consumer healthcare deal

    Australia's competition regulator said on Thursday it will not oppose GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business. The two pharmaceutical giants said in December they would combine ...

  • Comparing the EPS Growth Trajectories of PFE and GSK
    Market Realist 12 days ago

    Comparing the EPS Growth Trajectories of PFE and GSK

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?(Continued from Prior Part)EPS performanceOn its first-quarter earnings conference call, Pfizer (PFE) increased its 2019 adjusted diluted EPS guidance by $0.01 at the midpoint to

  • What Are Analysts Recommending for PFE and GSK in May?
    Market Realist 12 days ago

    What Are Analysts Recommending for PFE and GSK in May?

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?(Continued from Prior Part)Milestones achieved in MayOn May 6, Pfizer (PFE) issued a press release announcing the FDA’s approval of two oral formulations of tafamidis, Vyndaqel and Vyndamax,

  • Comparing the Relative Valuations of PFE and GSK
    Market Realist 12 days ago

    Comparing the Relative Valuations of PFE and GSK

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?First-quarter performancePfizer (PFE) and GlaxoSmithKline (GSK) reported their first-quarter earnings results on April 30 and May 1, respectively.In the first quarter, Pfizer surpassed

  • UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S
    Reuters 16 days ago

    UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

    A jury trial in a Delaware district court on Friday found that one of Vectura's U.S. patents was infringed by sales of three of GSK's Ellipta products in the United States, Vectura said. The jury found that GSK, which is also a UK-based pharmaceutical company, willfully infringed the patent, which Vectura said gives it the right to seek enhanced damages. Vectura expects to seek application of the 3 percent royalty to sales of the infringing products through the end of the patent term in mid-2021, it said.

  • Reuters 16 days ago

    UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

    British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018. A jury trial in a Delaware district court on Friday found that one of Vectura's U.S. patents was infringed by sales of three of GSK's Ellipta products in the United States, Vectura said. The jury found that GSK, which is also a UK-based pharmaceutical company, willfully infringed the patent, which Vectura said gives it the right to seek enhanced damages.

  • Reuters 17 days ago

    UK Stocks-Factors to watch on May 3

    (Adds company news items and futures) May 3 (Reuters) - Britain's FTSE 100 index is seen opening 1 point higher at 7,352 on Friday, according to financial bookmakers, while FTSE 100 futures were up 0.13 ...

  • Reuters 18 days ago

    GSK's 3-in-1 inhalable drug shows promise in asthma study

    The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta. The results come at a time when GSK is hit by generic competition for its blockbuster asthma treatment Advair and it looks to newer respiratory drugs to make up for declines in older medicines.

  • Reuters 18 days ago

    GSK's Trelegy Ellipta meets key goal in late-stage asthma study

    British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition. The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta. The results come at a time when GSK is hit by generic competition for its blockbuster asthma treatment Advair and it looks to newer respiratory drugs to make up for declines in older medicines.

  • Is GlaxoSmithKline a Buy?
    Motley Fool 18 days ago

    Is GlaxoSmithKline a Buy?

    Should investors buy into GlaxoSmithKline's turnaround story?

  • Thomson Reuters StreetEvents 18 days ago

    Edited Transcript of GSK.L earnings conference call or presentation 1-May-19 1:00pm GMT

    Q1 2019 GlaxoSmithKline PLC Earnings Call

  • GlaxoSmithKline plc (GSK) Q1 2019 Earnings Call Transcript
    Motley Fool 18 days ago

    GlaxoSmithKline plc (GSK) Q1 2019 Earnings Call Transcript

    GSK earnings call for the period ending March 31, 2019.